Eli Lilly and Company

Victor H Obungu

David Matthew Marquis

Andrew Ihor Korytko

Peter Edward Vaillancourt

Sheng-Bin Peng

Marcio Chedid

Shane Krummen Atwell

Andrew Charles Vendel

Cindy Takeuchi Dickerson

Ming Ye

Andrew Dixon Skora

Andrew Korytko

Richard Todd Pickard

Malgorzata Donata Gonciarz

Amita Datta-Mannan

Andrew H Korytko

Adam S Fleisher

Mark Mintun

John Randall Sims, Ii

Sarah Elisabeth Raines

Albert Lo

Megan Brittany Lannan

Robin Elizabeth Walsh

Yanfei L Ma

Elizabeth Anne West

The present disclosure relates to IL-34 antibodies, compositions comprising the same, and methods of using the antibodies and or compositions thereof for treating immune-mediated diseases such as neurodegenerative diseases, for example Alzheimer's Disease or a tauopathy disease.

Compounds and methods targeting interleukin-34

The present invention relates to IL-34 antibodies, compositions comprising the same, and methods of using the antibodies and or compositions thereof for treating immune-mediated diseases such as neurodegenerative diseases, for example Alzheimer's Disease or a tauopathy disease.

Antibodies to IL-34

Fusion compounds and methods of using same are provided which bind and neutralize human receptor activator of nuclear factor kappa-B ligand and are agonistic to parathyroid hormone receptor 1 signaling, said compounds are useful as agents for bone healing or treating conditions associated with bone mass loss or degeneration including treating osteoporosis.

Parathyroid hormone-anti-RANKL antibody fusion compounds

Antibodies which bind BTLA, and methods of using same, are provided, said antibodies are useful as agents for treating conditions associated with autoimmune disease including treating lupus.

BTLA agonist antibodies and uses thereof

Compounds are provided herein for inducing weight loss and for treating diabetes, dyslipidemia, NASH and/or obesity. Also provided are pharmaceutical compositions containing such compounds and therapeutic uses of such compounds and compositions, where such compounds act as GDF15 agonists with extended time of action and other advantageous properties.

Growth differentiation factor 15 agonist compounds and methods of using the same

Antibodies and methods of using these antibodies are provided which bind human and mouse receptor activator of nuclear factor kappa-B ligand, said antibodies are useful as agents for treating conditions associated with bone-related disorders or skeletal abnormalities caused by cancer.

Anti-RANKL antibodies and uses thereof

Bispecific antibody compounds, and methods of using same, are provided which bind and neutralize Dkk-1 and RANKL and which are useful as adjuncts to spinal fusion surgery or as agents for bone healing or treating conditions associated with bone loss or degeneration.

Anti-Dkk-1-anti-RANKL bispecific antibody compounds

The present invention provides antibodies that bind human CXCR4 and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful in the treatment of tumorigenesis, including tumor growth, invasion, angiogenesis, or metastasis.

Anti-CXCR4 antibodies

Growing community of inventors

Fishers, IN, United States of America

Victor H Obungu